$MXCT

MaxCyte (MXCT) reported Q2 2026 revenues ahead of expectations, with sequential growth driven by instrument placements, including its DTx platform. The company reduced net loss YoY and announced a multiplatform technology license partnership with Genentech, reflecting growing recognition of MaxCyte's technology. The partnership supports multiple programs and diversifies MaxCyte's revenue streams. Vertex's CASGEVY revenue grew 75% sequentially and 150% YoY, contributing to MaxCyte's SPL program-r

MaxCyte (MXCT) launched CHANGE-seq-BE and ONE-seq-BE assays to help therapeutic developers assess off-target risks in base editing therapies. The assays aim to identify potential off-target editing sites and genetic variants, supporting regulatory compliance and clinical development. MXCT's stock closed at $1.27, down 3.79%, and is down 0.47% in premarket trading.

MaxCyte, Inc. (NASDAQ: MXCT) launched CHANGE-seq-BE and ONE-seq-BE assays for off-target assessment in genome editing therapies. These assays, part of MaxCyte's SeQure service, aim to enhance safety evaluation for base editors, aligning with FDA guidelines. The company positions itself as a single-source provider for orthogonal nomination assays, supporting therapeutic developers in clinical development.

MaxCyte reported Q2 2026 sequential revenue growth after inventory drawdowns from a major customer and clinical program discontinuations. It signed a multi-platform enterprise partnership with Genentech and expects 2026 revenue guidance of $30m to $32m. Operating expenses fell 25% YoY. Company plans to use most of a $10m share repurchase program and expects mid-70s gross margins.

MaxCyte Inc (NASDAQ: MXCT) reported Q2 2026 EPS of $(0.08), better than the $(0.09) consensus, and revenue of $7.271M versus $6.475M consensus. Sales fell 14.53% year over year. The company signed a multi-platform technology license partnership with Genentech and reiterated 2026 guidance for $30M to $32M revenue.

MAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ MaxCyte Reports Second Quarter 2026 Financial Results · Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue · Reiterates Full Year 2026 Guidance · Repurchased a

MaxCyte (MXCT) said it signed a multi-platform technology license partnership with Genentech, a Roche Group member (RHHBY), to support next-generation cell therapy programs. Genentech will access MaxCyte’s ExPERT GTx platform and other technologies across research, clinical development, and manufacturing workflows. MaxCyte’s stock closed at $1.23, up 5.13% on the day.

MAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. MaxCyte, Inc._June 17, 2026 0001287098 false 0001287098 2026-06-17 2026-06-17 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ FORM 8-K ​ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of Report (Date of e

MaxCyte (NASDAQ: MXCT) reported its Q1 2026 financial results, showing a decrease in revenue to $9.7 million from $10.4 million in the prior year, though the net loss narrowed significantly to $4.8 million from $10.3 million due to reduced operating expenses. The decline in revenue was attributed to weaker core product and license sales, partially offset by an increase in Strategic Platform License milestones and royalties. The company maintained a high gross margin of 84% and expects its existing cash and investments to fund operations for at least the next 12 months.

MaxCyte (MXCT) exceeded first-quarter 2026 forecasts, reporting an EPS of -$0.04 against an expected -$0.08, and revenue of $9.7 million, significantly higher than the $7.3 million forecast. The company's stock rose 2.2% in aftermarket trading, driven by strong SPL program-related revenue growth despite an overall 7% decrease in total revenue year-over-year. MaxCyte reiterated its full-year 2026 guidance, expecting total revenue between $30 million and $32 million, and announced a $10 million share repurchase program, underscoring confidence in its long-term value and strategic investments.